MedSource establishes preferred provider relationship with Datatrial for e-clinical software nowEDC
HOUSTON, TX. -
MedSource
announced today that it has selected Datatrial's nowEDC™platform as its e-clinical software solution of choice. This latest decision demonstrates MedSource's commitment to provide the best possible value to their clients by offering a state-of-the-art electronic data capture (EDC) solution, nowEDC. The preferred relationship establishes nowEDC as the EDC platform of choice in exchange for preferred pricing for MedSource's full-service clients. "nowEDC has long been a preferred EDC platform by our clients and our staff," said MedSource president and CEO, Eric Lund. "The real-time dynamic reporting capabilities are a significant advantage for our biotech clients and any client who wants immediate access to their data, and who desires the ability to customize reports whenever they choose. It is a platform that provides more accuracy and flexibility than anything we have worked with in the industry. We are excited to offer nowEDC as a solution to our clients and expand our relationship with Datatrial."
Key Advantages of nowEDC software:
"We are excited that MedSource has chosen nowEDC as their EDC software of choice," said Datatrial CEO Emma Banks. "We have been a partner with MedSource for over a decade now and this decision further strengthens our relationship for future growth. We look forward to continuing to serve MedSource and their clients with our best in class nowEDC software and e-clinical and data solutions."
About MedSource
MedSource is recognized as an award winning, full-service clinical research organization (CRO) focusing on complex study designs and complex diseases with a particular expertise in oncology and central nervous system disorders. MedSource began as a specialized clinical monitoring group and has consistently expanded to add services and staff to increase the value we can deliver to our clients. With offices throughout North America, our focus on quality, consistency and transparency has been foundational to our growth.
About nowEDC
The nowEDC system provides data capture, verification and validation, query management, data extract, IWRS and real-time reporting in one integrated system. nowEDC is easy-to-use, fully validated and is highly configurable. The flexible aspects of nowEDC also make it a natural fit for handling both complex trial designs as well as adaptive clinical trials.
About Datatrial
Datatrial is a clinical biometrics and technology organization specializing in complete study delivery. We offer a full range of services including Data Management, Statistics and Medical Writing. With headquarters in Newcastle upon Tyne, UK and offices in Boston MA and BioHub at Alderley Park, UK we are very able to support global clinical development programs. Since 1999, we have been serving the pharmaceutical community through our commitment to service and quality in every aspect of the work that we do. With involvement in over 300 clinical trials, across 25 therapeutic areas and with extensive oncology experience we will work with you to develop a study plan that best fits your needs.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.